Anchyra Partners’s Edwards Lifesciences EW Stock Holding History

Anchyra Partners’s Portfolio EW Stock Details EW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$242K	Buy	+2,677	New	+$224K	0.06%	279

Other funds holding EW

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Nordea Investment Management Stockholm, Sweden $123B AUM 38.85% 1-Year Est. Return

Universal-Beteiligungs- und Servicegesellschaft Frankfurt Am Main, Germany $65.4B AUM 39.83% 1-Year Est. Return

Anchyra Partners's EW Position: Q2 2026 in Review

Anchyra Partners opened a new position in Edwards Lifesciences (EW) in Q2 2026: 2,677 shares worth $242K. The stake represents 0.06% of the portfolio and ranks #279 among its holdings.

774 funds tracked by Wall St. Rank hold EW as of Q2 2026.

Anchyra Partners held 2,677 shares of Edwards Lifesciences worth $242K as of Q2 2026.
Edwards Lifesciences was a new Anchyra Partners position in Q2 2026.
Edwards Lifesciences made up 0.06% of Anchyra Partners's portfolio in Q2 2026, its #279 holding.
774 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.

Based on Anchyra Partners's 13F filing for Q2 2026, filed 23 Jul 2026.